BR0102211A - Composição farmacêutica para o tratamento da obesidade ou para facilitar ou promover a perda de peso - Google Patents

Composição farmacêutica para o tratamento da obesidade ou para facilitar ou promover a perda de peso

Info

Publication number
BR0102211A
BR0102211A BR0102211-3A BR0102211A BR0102211A BR 0102211 A BR0102211 A BR 0102211A BR 0102211 A BR0102211 A BR 0102211A BR 0102211 A BR0102211 A BR 0102211A
Authority
BR
Brazil
Prior art keywords
obesity
weight loss
facilitate
treatment
pharmaceutical composition
Prior art date
Application number
BR0102211-3A
Other languages
English (en)
Inventor
Jotham Wadswoth Coe
Steven Bradley Sands
Brian Thomas O Neill
Robert Lee Dow
Edmund Patrick Harrigan
Eric Jacob Watsky
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0102211A publication Critical patent/BR0102211A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: "COMPOSIçãO FARMACêUTICA PARA O TRATAMENTO DA OBESIDADE OU PARA FACILITAR OU PROMOVER A PERDA DE PESO". Composições farmacêuticas são reveladas para o tratamento da obesidade, de uma condição de excesso de peso e do comer compulsivamente. As composições farmacêuticas compreendem uma combinação terapeuticamente eficaz de um agonista parcial do receptor de nicotina e um agente antiobesidade ou promotor ou facilitador de perda de peso e um veículo farmaceuticamente aceitável. O método de utilização destes compostos é também revelado.
BR0102211-3A 2000-06-02 2001-05-30 Composição farmacêutica para o tratamento da obesidade ou para facilitar ou promover a perda de peso BR0102211A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20885600P 2000-06-02 2000-06-02

Publications (1)

Publication Number Publication Date
BR0102211A true BR0102211A (pt) 2002-03-05

Family

ID=22776308

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0102211-3A BR0102211A (pt) 2000-06-02 2001-05-30 Composição farmacêutica para o tratamento da obesidade ou para facilitar ou promover a perda de peso

Country Status (5)

Country Link
US (2) US20020010192A1 (pt)
EP (1) EP1159970A3 (pt)
JP (1) JP2002012558A (pt)
BR (1) BR0102211A (pt)
CA (1) CA2349388A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002234836B2 (en) * 2001-04-20 2007-08-23 Pfizer Products Inc. Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
NZ534757A (en) * 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US7074812B2 (en) * 2002-08-02 2006-07-11 Nutraleutical Development Corporation Development of muscle mass in a mammal
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
WO2005000806A2 (en) 2003-06-10 2005-01-06 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
TW200518768A (en) * 2003-11-17 2005-06-16 Pepgen Corp Methods for treatment of obesity and for promotion of weight loss

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018798A1 (en) * 1996-10-30 1998-05-07 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
AU748468B2 (en) * 1997-09-16 2002-06-06 Transnexus, Inc. Internet telephony call routing engine
DE69839131T3 (de) * 1997-12-31 2015-05-07 Pfizer Products Inc. Arylkondensierte azapolycyclische derivate
US6584093B1 (en) * 1998-08-25 2003-06-24 Cisco Technology, Inc. Method and apparatus for automatic inter-domain routing of calls

Also Published As

Publication number Publication date
EP1159970A3 (en) 2003-03-05
US20020010192A1 (en) 2002-01-24
JP2002012558A (ja) 2002-01-15
US20030176457A1 (en) 2003-09-18
CA2349388A1 (en) 2001-12-02
EP1159970A2 (en) 2001-12-05

Similar Documents

Publication Publication Date Title
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
GT199700009AA (es) Terapia combinada para la osteoporosis
BR0212986A (pt) Derivados de imizadol-4-carboxamida, preparação e uso dos mesmos para tratamento de obesidade
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
BR9711805A (pt) Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
DE69719798D1 (de) Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit
KR930003912A (ko) 울혈성 심장 마비 치료법
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
BR9809951A (pt) Método para tratamento da obesidade
BR0112661A (pt) Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2000015205A3 (en) Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes
BR0103169A (pt) Composição farmacêutica para o tratamento do distúrbio de hiperatividade de déficit de atenção (adhd)
BR0102211A (pt) Composição farmacêutica para o tratamento da obesidade ou para facilitar ou promover a perda de peso
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
BR0105787A (pt) Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico
BR9908885A (pt) Medicamento para a profilaxia e/ou tratamento de mastocarcinoma, compreendendo um inibidor esteróide de aromatase
BG103060A (bg) 19- нор- холан стероиди като неврохимични инициатори на промяната в действието на хипоталамуса причовек
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
WO1999045909A3 (en) Use of nitrone compounds for the inhibition of angiogenesis
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2012 DE 28/07/2009.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/439 (2006.01), A61P 3/04 (2006.01)